Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Pages: 58 Published: May 27, 2022 Report Code: GDHC063CL

The Alport syndrome pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products, late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for Alport syndrome.  The report also analyzes the clinical and commercial landscapes of Alport syndrome, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

Alport syndrome (AS) is a genetically and phenotypically heterogeneous, progressive hereditary renal disease that is characterized by sensorineural hearing loss and ocular abnormalities.

Which are the key regions in the Alport syndrome pipeline drugs market?

The key regions in the Alport syndrome pipeline drugs market are Asia-Pacific, Europe and North America. Of all the trials initiated in Alport syndrome over the past 10 years, single-country trials were most numerous in the Asia-Pacific region.

Which are the key development stages in the Alport syndrome pipeline drugs market?

The key development stages in the Alport syndrome pipeline drugs market are pre-registration, phase I, phase II, preclinical, and discovery. Preclinical stage has the highest share amongst all the others.

Alport syndrome pipeline drugs market, by development stage

Alport syndrome pipeline drugs market, by development stageFor more development stage insights, download a free report sample

Which are the key countries for clinal trials in the Alport syndrome pipeline drugs market?

The key countries for clinical trials in the Alport syndrome pipeline drugs market are the US, Germany, Spain, Japan, Australia, the UK, China, South Korea, France and Italy. The US is the leading country in terms of the number of trial sites utilized for Alport syndrome trials over the past 10 years.

Alport syndrome pipeline drugs market, by countries

Alport syndrome pipeline drugs market, by countriesFor more country insights, download a free report sample

Which are the key molecule types in the Alport syndrome pipeline drugs market?

The key molecule types in the Alport syndrome pipeline drugs market are small molecule, oligonucleotide, and biologic. Small molecule has the highest share in the Alport syndrome pipeline drugs market.

Alport syndrome pipeline drugs market, by molecule types

Alport syndrome pipeline drugs market, by molecule typesFor more molecule types insights, download a free report sample

Which are the key MoA in the Alport syndrome pipeline drugs market?

The key MoA in the Alport syndrome pipeline drugs market are receptor antagonist, enzyme inhibitor, protein and peptide activator, ion channel activator, biological factor inhibitor, protein and peptide inhibitor, genes, nucleic acid & related components inhibitor. Receptor antagonist has the highest number of pipeline products.

Alport syndrome pipeline drugs market, by MoA

Alport syndrome pipeline drugs market, by MoAFor more MoA insights, download a free report sample

Which are the key RoA in the Alport syndrome pipeline drugs market?

The key RoA in the Alport syndrome pipeline drugs market are oral and injection. Oral has the highest number of pipeline products.

Alport syndrome pipeline drugs market, by RoA

Alport syndrome pipeline drugs market, by RoAFor more RoA insights, download a free report sample

Which are the key sponsors in the Alport syndrome pipeline drugs market?

The key sponsors in the Alport syndrome pipeline drugs market are Reata Pharmaceutical Inc, Eegulus Therapeutics Inc, River 3 Renal Corp, Genzyme Corp, Universitaetsmedizin Goettingen, Shanghai Children’s Hospital, Chinook Therapeutics Inc, TMC Pharma Services Ltd, and Others. Of the clinical trials initiated by commercial sponsors in Alport syndrome over the past 10 years, Reata Pharmaceuticals and Regulus Therapeutics have the highest number of completed trials.

Alport syndrome pipeline drugs market, by sponsors

Alport syndrome pipeline drugs market, by sponsorsTo know more about sponsors, download a free report sample

Market report overview

Key regions Asia-Pacific, Europe and North America
Key Countries The US, Germany, Spain, Japan, Australia, the UK, China, South Korea, France and Italy
Key Development Stage Pre-Registration, Phase I, Phase II, Preclinical, and Discovery
Key MoA Receptor Antagonist, Enzyme Inhibitor, Protein and Peptide Activator, Lon Channel Activator, Biological Factor Inhibitor, Protein And Peptide Inhibitor, Genes, Nucleic Acid & Related Components Inhibitor
Key RoA Oral and Injection
Key Molecule Types Small Molecule, Oligonucleotide, and Biologic
Key Sponsors Reata Pharmaceutical Inc, Eegulus Therapeutics Inc, River 3 Renal Corp, Genzyme Corp, Universitaetsmedizin Goettingen, Shanghai Children’s Hospital, Chinook Therapeutics Inc, TMC Pharma Services Ltd, and Others

Scope

GlobalData’s Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

  • Components of the report include:
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Alport Syndrome market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Alport Syndrome market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents (PowerPoint Deck)

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

5 Pipeline Drugs Assessment

5.1 Phase III Pipeline Drugs

5.2 Overview by Development Stage

5.3 Overview by Molecule Type

5.4 Overview by Mechanism of Action

5.5 Overview by Route of Administration

5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

6 Clinical Trials Assessment

6.1 Historical Overview

6.2 Overview by Phase

6.3 Overview by Status

6.4 Overview by Phase for Ongoing and Planned Trials

6.5 Trials with Virtual Components

6.6 Geographic Overview

6.7 Single-Country and Multinational Trials by Region

6.8 Top 20 Sponsors with Breakdown by Phase

6.9 Top 20 Sponsors with Breakdown by Status

6.10 Overview by Endpoint Status

6.11 Overview by Race and Ethnicity

6.12 Enrollment Data

6.13 Top 20 countries for Trial Sites

6.14 Top 20 Sites Globally

6.15 Feasibility Analysis – Geographic Overview

6.16 Feasibility Analysis – Benchmark Models

7 Deals Landscape

7.1 Mergers, Acquisitions, and Strategic Alliances by Region

7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

10.1 Methodology

10.2 Methodology – PTSR and LoA Analysis

10.3 About the Authors

10.4 Contact Us

10.5 Disclaimer

Frequently Asked Questions

$3495

Can be used by individual purchaser only

$10485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.